{"disease":{"id":"secondary-acute-myeloid-leukemia","name":"secondary acute myeloid leukemia"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00898079","title":"Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2545,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01005277","title":"Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02085408","title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":727,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":true},{"nct_id":"NCT01307579","title":"Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":517,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT02115295","title":"Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":508,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02044796","title":"Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":199,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT05554419","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":184,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01627041","title":"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":178,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02397720","title":"Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02809222","title":"Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls","phase":"NA","overall_status":"COMPLETED","enrollment_count":138,"lead_sponsor_name":"University Hospital, Tours","has_results":false},{"nct_id":"NCT00658814","title":"Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02727803","title":"Personalized NK Cell Therapy in CBT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT03226418","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT02530034","title":"Hu8F4 in Treating Patients With Advanced Hematologic Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01139970","title":"Veliparib and Temozolomide in Treating Patients With Acute Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00101179","title":"MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01760655","title":"Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT01238211","title":"Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04284787","title":"BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03041688","title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":58,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03630991","title":"Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":58,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02286726","title":"CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":56,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02890329","title":"Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":54,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03874052","title":"Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":51,"lead_sponsor_name":"Jennifer Saultz","has_results":false},{"nct_id":"NCT05584761","title":"Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT01839240","title":"Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04214249","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":49,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03747757","title":"Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01640301","title":"Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT01028716","title":"Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":46,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT02583893","title":"Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT02642965","title":"Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT05807932","title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT00531232","title":"A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT04848974","title":"Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06928662","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT01588015","title":"Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03494569","title":"Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03333486","title":"Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT02071901","title":"Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":31,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT02159495","title":"Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":31,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03009240","title":"Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05513131","title":"Clinical Study Protocol of Venetoclax Combined With Azacitidine and Harringtonine in the Treatment of sAML","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT02126553","title":"Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05672147","title":"CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":27,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02299518","title":"Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Alice Mims","has_results":false},{"nct_id":"NCT04269213","title":"CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":21,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}